Late-breaking data show infant respiratory syncytial virus (RSV) hospitalizations reduced by 69% in Spain following Beyfortus-only immunization targeted to all infants and 26.7% in the UK ...

Late-breaking data show infant respiratory syncytial virus (RSV) hospitalizations reduced by 69% in Spain following Beyfortus-only immunization targeted to all infants and 26.7% in the UK following ...

Beyfortus administration can be timed to coincide with the RSV season. Beyfortus has been approved for use in the US, the EU, China, Japan, and many other countries around the world.

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

AstraZeneca and Sanofi's Beyfortus, a monoclonal antibody approved in July 2023, is the first preventive option specifically designed to protect the broad infant population through its first RSV ...

On Tuesday, TD Cowen maintained a Hold rating on Sanofi (NASDAQ: NASDAQ: SNY) shares with a consistent price target of $67.00.Currently trading at $52.89, the stock shows potential upside ...